Framework nucleic acid-programmed aptamer–paclitaxel conjugates as targeted therapeutics for triple-negative breast cancer

A precisely structured framework nucleic acid-programmed aptamer–paclitaxel conjugate with well-defined paclitaxel loading dose is fabricated, enabling the regulation of receptor–aptamer affinity to facilitate tumor-targeted chemotherapy.